Bevacizumab for Central Retinal Vein Occlusion Study

A Prospective, Randomized, Controlled Study on Intravitreal Bevacizumab (Avastin) for Central Retinal Vein Occlusion (CRVO)

Central retinal vein occlusion is a leading cause of severe visual impairment. Until now, no treatment has been available to improve visual acuity. The present study intends to investigate if intravitreal bevacizumab can improve visual acuity as compared to sham-treated control patients.

Inclusion Criteria:

• CRVO with duration < 6 months
• Visual acuity of 20/800 to 20/50

Exclusion Criteria:

• CRVO with duration of > 6 months
• previous treatment with anti-angiogenic drugs